explore -WSS

explore

author：explore 2025-08-23 08:57:29 - browse：59

insulin biosimilar — Last week, the FDA released a trio of guidelines clarifying the way they plan to evaluate devices that go through the 510(k) pathway. Jacquelyn Martin/AP

Five years after promising to fix a flawed regulatory pathway widely used by medical device manufacturers, the Food and Drug Administration has issued new guidelines to improve its so-called 510(k) program that has long been lambasted for letting risky devices fall through the cracks.

Most medical device companies do not have to test their products on people in order to secure clearance from the FDA — they simply have to show they’re “substantially equivalent” to devices already on the market, called “predicates.” This process is the 510(k) pathway, and accounts for the vast majority of new medical devices launched on the market each year. Devices cleared through this pathway include X-ray machines, muscle stimulators, and wheelchairs.

Last week, the FDA released a trio of guidelines clarifying the way it plans to evaluate devices that go through the 510(k) pathway. The agency is asking manufacturers to avoid predicate devices that were recalled due to a “design-related” issue or have “unmitigated” safety concerns. Manufacturers should submit flow charts explaining why they chose their predicate device. If they have to choose one with a recall history or safety issues, they should explain how the new device addresses those problems. The FDA may also ask the manufacturer for clinical data in this case.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Neuroscience startup Neumora files for IPO

WSS

Organ aging and disease risk measured by new blood test

Study finds new variant for Parkinson’s in African populations

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

As pharma fights Medicare drug negotiation, hospitals, docs silent

CDC director unscathed in first congressional testimony

In science, is the line between industry and academia shifting?

focus

explore

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

What don’t we know about an Alzheimer’s drug side effect?

Peter Hotez and the public health issue of online harassment

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Moonlake's readout produced a cash windfall. Risks remain

Drug firms test therapies to halt Alzheimer’s before symptoms arise

The cancer drug shortage isn’t new — and neither are the solutions

Despite FDA concern, risk that CAR

Dobbs anniversary: the lost opportunity of abortion as health care

What don’t we know about an Alzheimer’s drug side effect?

Wikipedia

CDC director unscathed in first congressional testimony

As pharma fights Medicare drug negotiation, hospitals, docs silent

As pharma fights Medicare drug negotiation, hospitals, docs silent

How to pay for weight loss drugs and save Medicare

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Cigna, Humana reportedly in talks to merge

entertainment

explore

knowledge

knowledge